Sort   by:  
 Page size 
UnknownDifferential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab.
Not available
S-EPMC6628172 | biostudies-literature
UnknownDevelopment and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study.
Not available
S-EPMC8536532 | biostudies-literature
UnknownPredictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.
Not available
S-EPMC7072584 | biostudies-literature
UnknownIs there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?
Not available
S-EPMC6895963 | biostudies-literature
UnknownExtending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients.
Not available
S-EPMC11130267 | biostudies-literature
UnknownBurden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors.
Not available
S-EPMC10701119 | biostudies-literature
Sort   by:  
 Page size